文献速递前列腺癌

非转移性前列腺癌患者雄激素剥夺治疗早期前列腺特异性抗原进展时,针对68Ga-前列腺特异性膜抗原与18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描检出病灶的立体定向放疗:一项前瞻性单中心研究

Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study.
PubMed 文献 · Eur Urol Oncol · 2022-03-16

本前瞻性单中心研究于2019年4月至2020年10月筛查74例非转移性前列腺癌且ADT期间早期PSA进展(PSA≤2 ng/ml)患者,采用双示踪剂PET/CT引导SBRT。SBRT组中位无转移生存期未达到,ADT组为11.0个月(HR 4.69,95%CI 2.92-25.0,p<0.001);SBRT组86%患者PSA反应>90%,无≥3级不良事件。

要点

  • 双示踪剂PET/CT引导SBRT相比单用ADT可延长无转移生存期(未达到 vs 11.0个月;HR 4.69,p<0.001)。
  • SBRT组与N-/M-组中位无转移生存期无显著差异(p=0.261)。
  • SBRT组86%患者PSA反应>90%,无≥3级不良事件。

核心结论

  • 双示踪剂PET/CT引导的SBRT相比单用ADT局部控制率更优,且毒性轻微。

研究设计与样本

  • 前瞻性单中心研究,2019年4月至2020年10月连续筛查74例非转移性前列腺癌且ADT期间早期PSA进展(PSA≤2 ng/ml)患者。
  • 推荐对≤5个非内脏转移灶患者行SBRT(SBRT组),无可检测转移灶者(N-/M-组)及拒绝SBRT者(ADT组)继续ADT。
  • 7例被排除于MFS分析:2例有阿比特龙治疗史,5例转移灶超过5个。
  • 中位随访21.4个月,采用Kaplan-Meier法评估无转移生存期,不良事件按CTCAE v4.0评价。

主要发现

  • 74例筛查患者中54例有转移,17例为PSMA-/FDG+病变。
  • 中位PSA为0.59 ng/ml,中位PSA倍增时间为4.56个月。
  • ADT组中位MFS短于SBRT组(11.0个月 vs 未达到;HR 4.69,95%CI 2.92-25.0;p<0.001)。
  • ADT组中位MFS短于N-/M-组(11.0个月 vs 未达到;HR 8.78,95%CI 4.04-40.30;p<0.001)。
  • SBRT组与N-/M-组中位MFS无显著差异(p=0.261)。

关键数值与推荐

  • SBRT推荐用于≤5个非内脏转移灶的非转移性前列腺癌患者。
  • PSA反应>90%在SBRT组达到86%。
  • SBRT后无≥3级不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 非随机设计是主要研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual-tracer positron emission tomography/computed tomography (PET/CT) with a 68Ga-labelled prostate-specific membrane antigen (PSMA) ligand and 18F-fluorodeoxyglucose (FDG) improves detection of metastatic heterogeneity and burden in patients with nonmetastatic prostate cancer (nmPCa). However, there is limited prospective evidence regarding its impact on the efficacy of stereotactic body radiotherapy (SBRT). OBJECTIVE: To evaluate metastasis-free survival (MFS) and toxicity after SBRT to dual-tracer PET/CT-detected metastases in patients with nmPCa and early prostate-specific antigen (PSA) progression on androgen deprivation therapy (ADT; PSA ≤2 ng/ml). DESIGN, SETTING, AND PARTICIPANTS: Patients were prospectively screened using dual-tracer PET/CT between April 2019 and October 2020. SBRT was recommended for patients with five or fewer nonvisceral metastases (SBRT group). Patients without detectable metastases (N-/M- group) and those who refused SBRT (ADT group) continued to receive ADT. Patients were followed with conventional imaging. INTERVENTION: SBRT to each PET/CT-detected metastasis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier methods were used to determine MFS. Toxicity was evaluated using Common Terminology Criteria for Adverse Event v4.0. RESULTS AND LIMITATIONS: Seventy-four consecutive patients were screened. The median PSA and PSA doubling time were 0.59 ng/ml and 4.56 mo, respectively. Overall, 54 patients had metastases and 17 had PSMA-/FDG+ disease. Seven patients were excluded from the MFS analysis, including two with a history of abiraterone treatment and five with more than five metastases. The median follow-up was 21.4 mo. The ADT group had shorter MFS than the SBRT group (11.0 mo vs not reached; hazard ratio [HR] 4.69, 95% confidence interval [CI] 2.92-25.0; p < 0.001) and the N-/M- group (11.0 mo vs not reached; HR 8.78, 95% CI 4.04-40.30; p < 0.001). There was no significant difference in median MFS between the SBRT group and the N-/M- group (p = 0.261). A PSA response >90% was achieved by 86% of patients in the SBRT group. There were no grade ≥3 adverse events after SBRT. The nonrandomized design is the major study limitation. CONCLUSIONS: Dual-tracer PET/CT-guided SBRT delivered superior local control rates in comparison to ADT alone and had minimal toxicity. PATIENT SUMMARY: We investigated metastasis-targeted radiotherapy for patients with up to five prostate cancer metastases detected with two different radioisotope scans. Our results show that this approach yields promising metastasis-free survival and low toxicity.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Pan J, Wei Y, Zhang T, et al. Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. Eur Urol Oncol. 2022. PMID: 35304107. doi:10.1016/j.euo.2022.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。